Navigation Links
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Date:9/11/2007

KIRKLAND, Wash., Sept. 11 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation of Cleveland, Ohio. The goal of the collaboration is to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds.

CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The Company's first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80% compared to conventional methods, which achieve only up to about 7%. Importantly, CellCyte's product can be delivered intravenously through the patients' circulatory system without an invasive procedure.

The lead investigators of the project at Cleveland Clinic Foundation are Dr. Wilson Tang M.D. and Dr. Sathyamangla Prasad Ph.D., both accomplished and renowned scientists in the field of cardiac biology. Dr. Tang is also a physician and key opinion leader in cardiac medicine.

The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide valuable novel information that will increase the understanding of cardiac regeneration and will thereby sup
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Conn. , July 2, 2015 Numotion,s ... Executive Officer announced that Tamas Feitel has ... Feitel joins Numotion after a highly successful 18 year ... leadership roles driving strategy, profitability, and productivity to result ... most recent position was Chief Financial Officer for GE ...
(Date:7/2/2015)... July 2, 2015 The report ... Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & ... to 2020", Silage Inoculants & Enzymes Market is expected ... of 4.0% from 2015 to 2020. ... spread through 194 P ages and ...
(Date:7/2/2015)... de julio de 2015 BGI anunció hoy ... alto rendimiento en Hong Kong ... Pathologists (CAP). La instalación de BGI en Hong ... de próxima generación que recibe la certificación CAP en ... estándar en prácticas de laboratorio clínico. Junto con el ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... Texas, Feb. 23, 2012   ULURU Inc. (NYSE ... Goods Certificate has been issued by the Therapeutic Goods ... Commenting on the approval in Australia, Kerry P. ... another important milestone in the worldwide commercialization of Altrazeal®.  ...
... Feb. 23, 2012 A new imaging efficiency ... Medicaid Services (CMS) to reduce CT scans in ... are performing CT scans inappropriately, according to a ... of Emergency Medicine ("Assessment of Medicare,s Imaging ...
Cached Medicine Technology:ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP 2
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... 02, 2015 , ... Following the recent report by JAMA Internal Medicine ... merely overweight Americans, Samir Becic emphatically declared a war on obesity in the United ... Becic said. "We must understand the magnitude of this discovery. For that reason, I ...
(Date:7/2/2015)... ... , ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, ... his first poem, and three years later he was publishing an entire book of poetry. ... the world. "I have always believed that the best way to lift yourself up, is ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of ... cross-country walk to raise awareness and money for the Pulmonary Hypertension Association (PHA). ... at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... than 27 million adults currently suffer from osteoarthritis, which is ... have been unable to diagnose patients with arthritis until they ... By the time these symptoms are present, it is ... to be effective. Now, a research team from the ...
... By Alan Mozes HealthDay Reporter , TUESDAY, May ... restored partial mobility to the hand of a quadriplegic patient. ... bone in his neck, and it was the specific location ... the spine itself. Instead, the team focused on the ...
... Journal of Thoracic Oncology says molecular biomarkers in ... additional predictive technique for lung cancer screening. , Since ... the positive CT screening results were false positive, scientists have ... research focused on a way to determine if the nodules ...
... HealthDay Reporter , TUESDAY, May 15 (HealthDay News) -- Should Americans ... it to determine whether they,re infected with the virus that causes ... plans to debate this question Tuesday, and the answer the panel ... HIV testing. FDA advisory panel recommendations are not binding, but ...
... Alberta provides new insight into treatment patterns for people ... will help physicians improve care strategies for patients provincewide. ... School of Public Health, says the study of more ... step to addressing gaps in care and ensuring that ...
... death rate in older Americans is likely the effect ... from the Johns Hopkins Center for Injury Research and ... mortality rate occurred immediately following the 1999 introduction of ... suggesting a major change in the way deaths were ...
Cached Medicine News:Health News:New biomarker test predicts arthritis at much earlier stage, MU researchers say 2Health News:Doctors Restore Some Hand Function to Quadriplegic Patient 2Health News:Doctors Restore Some Hand Function to Quadriplegic Patient 3Health News:FDA Panel to Consider At-Home HIV Test 2Health News:FDA Panel to Consider At-Home HIV Test 3Health News:Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment 2Health News:Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment 3Health News:Reported increase in older adult fall deaths due to improved coding 2
... Assisted Lipoplasty Device uses a 2-mm reciprocating movement ... movement of the cannula in tissue. So less ... fibrous tissue. That makes the lipoplasty procedure easier ... your mind to learn that the PAL® is ...
... in.hg.@sea level. Incredibly quiet, yet very powerful. ... systems at one time eliminates the need ... Standard canister set-up is for Abbott 2000ml ... c-UL and CE marks. Includes a wireless ...
... cohesive is a new term being used today to ... more liquid fill that may have been used in ... new science, this is not new technology cohesive ... describe the sticking together nature of the gel. All ...
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
Medicine Products: